Literature DB >> 17299742

Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes.

Robert H Baloh1, Wojtek Rakowicz, Robert Gardner, Alan Pestronk.   

Abstract

This study was performed to determine whether there are distinctive features to the pattern of muscle denervation in motor neuron disease. We first compared muscle biopsies from patients with amyotrophic lateral sclerosis (ALS) or Kennedy's disease with other causes of denervation. Groups of atrophic muscle fibers, with individual groups containing both fiber types I and II, occurred frequently in motor neuron disease but not other causes of denervation. We then identified 11 additional muscle biopsies with frequent atrophic groups containing mixed fiber types. Chart review revealed that 10 patients had a final diagnosis of motor neuron disease or ALS and one had multifocal motor neuropathy. We conclude that muscle biopsy may have diagnostic utility early in the course of motor neuron disease. The muscle biopsy pattern of frequent atrophic groups containing mixed fiber types should suggest a diagnosis of a motor neuron syndrome or motor neuropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17299742     DOI: 10.1002/mus.20755

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

Review 1.  Innervation and neuromuscular control in ageing skeletal muscle.

Authors:  Russell T Hepple; Charles L Rice
Journal:  J Physiol       Date:  2015-12-21       Impact factor: 5.182

Review 2.  Systems biology of skeletal muscle: fiber type as an organizing principle.

Authors:  Sarah M Greising; Heather M Gransee; Carlos B Mantilla; Gary C Sieck
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-07-18

3.  Two distinct skeletal muscle microRNA signatures revealing the complex mechanism of sporadic ALS.

Authors:  Evrim Aksu-Menges; Burcu Balci-Hayta; Can Ebru Bekircan-Kurt; Ayse Tulay Aydinoglu; Sevim Erdem-Ozdamar; Ersin Tan
Journal:  Acta Neurol Belg       Date:  2021-07-09       Impact factor: 2.396

Review 4.  Functional impact of sarcopenia in respiratory muscles.

Authors:  Jonathan E Elliott; Sarah M Greising; Carlos B Mantilla; Gary C Sieck
Journal:  Respir Physiol Neurobiol       Date:  2015-10-20       Impact factor: 1.931

5.  Smoke-induced neuromuscular junction degeneration precedes the fibre type shift and atrophy in chronic obstructive pulmonary disease.

Authors:  Sophia Kapchinsky; Madhusudanarao Vuda; Kayla Miguez; Daren Elkrief; Angela R de Souza; Carolyn J Baglole; Sudhakar Aare; Norah J MacMillan; Jacinthe Baril; Paul Rozakis; Vita Sonjak; Charlotte Pion; Mylène Aubertin-Leheudre; Jose A Morais; R Thomas Jagoe; Jean Bourbeau; Tanja Taivassalo; Russell T Hepple
Journal:  J Physiol       Date:  2018-05-19       Impact factor: 5.182

Review 6.  Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments.

Authors:  Luc Dupuis; Andoni Echaniz-Laguna
Journal:  Curr Drug Targets       Date:  2010-10       Impact factor: 3.465

7.  Characterization of intercostal muscle pathology in canine degenerative myelopathy: a disease model for amyotrophic lateral sclerosis.

Authors:  Brandie R Morgan; Joan R Coates; Gayle C Johnson; Alyssa C Bujnak; Martin L Katz
Journal:  J Neurosci Res       Date:  2013-09-16       Impact factor: 4.164

8.  TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.

Authors:  Iga Wegorzewska; Shaughn Bell; Nigel J Cairns; Timothy M Miller; Robert H Baloh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-15       Impact factor: 11.205

9.  Time-course and characterization of orolingual motor deficits in B6SJL-Tg(SOD1-G93A)1Gur/J mice.

Authors:  S E Smittkamp; J W Brown; J A Stanford
Journal:  Neuroscience       Date:  2007-10-30       Impact factor: 3.590

Review 10.  Applying proteomics to the diagnosis and treatment of ALS and related diseases.

Authors:  Robert Bowser; David Lacomis
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.